Evidence map›Paper›PMID 36993517›Full record

ArticlebioRxiv : the preprint server for biology2023

Targeted DNA integration in human cells without double-strand breaks using CRISPR RNA-guided transposases.

George D Lampe, Rebeca T King, Tyler S Halpin-Healy, Sanne E Klompe, Marcus I Hogan, Phuc Leo H Vo, Stephen Tang, Alejandro Chavez, Samuel H Sternberg

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

George D LampeDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Rebeca T KingDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Tyler S Halpin-HealyDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Sanne E KlompeDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Marcus I HoganDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Phuc Leo H VoDepartment of Molecular Pharmacology and Therapeutics, Columbia University, New York, NY, USA.
Stephen TangDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Alejandro ChavezDepartment of Pathology and Cell Biology, Columbia University, New York, NY, USA.
Samuel H SternbergDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA.
Columbia University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007367 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI REINER, STEVEN L · 1985 to 2021
$25.1M
TRAINING IN CELLULAR, MOLECULAR AND BIOPHYSICAL STUDIEST32GM008224 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI LIEM, RONALD K. · 1987 to 2021
$9.9M
Medical Scientist Training ProgramT32GM145440 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STEVEN L REINER · 2022 to 2026
$7.3M
Leveraging Programmable Integrases for Human Genome EngineeringDP2HG011650 · NHGRI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STERNBERG, SAMUEL HENRY · 2020 to 2020
$2.4M
Protein tagging at scale to enable functional genomic studiesR21HG011855 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHAVEZ, ALEJANDRO · 2021 to 2021
$633k
Leveraging CRISPR RNA-guided DNA Transposases for Gene Insertion at the CFTR LocusF31HL167530 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KING, REBECA TERESA · 2023 to 2025
$153k
NHGRI NIH HHS DP2 HG011650NHGRI NIH HHS R21 HG011855NHLBI NIH HHS F31 HL167530NIGMS NIH HHS T32 GM007367NIGMS NIH HHS T32 GM008224NIGMS NIH HHS T32 GM145440
6 · The paper itself

Abstract

Traditional genome-editing reagents such as CRISPR-Cas9 achieve targeted DNA modification by introducing double-strand breaks (DSBs), thereby stimulating localized DNA repair by endogenous cellular repair factors. While highly effective at generating heterogenous knockout mutations, this approach suffers from undesirable byproducts and an inability to control product purity. Here we develop a system in human cells for programmable, DSB-free DNA integration using Type I CRISPR-associated transposons (CASTs). To adapt our previously described CAST systems, we optimized DNA targeting by the QCascade complex through a comprehensive assessment of protein design, and we developed potent transcriptional activators by exploiting the multi-valent recruitment of the AAA+ ATPase, TnsC, to genomic sites targeted by QCascade. After initial detection of plasmid-based transposition, we screened 15 homologous CAST systems from a wide range of bacterial hosts, identified a CAST homolog from

Identifiers

PMID36993517
PMCPMC10055298
OpenAlexW4327862325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.